Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
'You're no longer my sister' - rows erupt as war divides Iranian families - 2Nigeria warns its citizens in South Africa to be cautious after march turns violent
- 3The breakout star of NASA's Artemis 2 moon mission isn't an astronaut — it's the space toilet
- 4Vote in favor of the pasta that makes good dieting pleasant!
- 5Bondi Beach survivor criticizes police for inaction during terror attack
- The Way to Monetary Freedom: A Viable Aide
- Step by step instructions to Get the Best Vehicle Rent Arrangement: Insider Tips and Systems
- 10 Activities to Lift Your Consume and Bust Your Stomach
- Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- Israel reports first missile fire from Yemen since start of Iran war
- Minneapolis ICE shooting live updates: Protests continue over agent's killing of Renee Nicole Good; Walz puts National Guard on standby
- Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- Antimatter took to the road for the very first time. Here’s why it matters
- New Jordan security fence could be done in early 2028
